Pfizer (PFE) Other Non Operating Income (2009 - 2026)
Pfizer (PFE) posted quarterly Other Non Operating Income of -$861.0 million for Q1 2026, up 9.65% year-over-year from -$785.2 million in Q1 2025, and up 80.93% quarter-over-quarter from -$4.5 billion in Q4 2025.
Pfizer (PFE) Other Non Operating Income (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Other Non Operating Income for 18 consecutive years, with -$861.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 9.65% year-over-year to -$861.0 million; the TTM figure through Mar 2026 stood at -$6.6 billion (down 39.01% YoY), while the FY2025 annual figure was -$6.7 billion, down 53.24% from the prior year.
- Other Non Operating Income advanced to -$861.0 million in Q1 2026 per PFE's latest filing, from -$4.5 billion in the prior quarter.
- Across five years, Other Non Operating Income topped out at $159.0 million in Q4 2023 and bottomed at -$4.5 billion in Q4 2025.
- Historically, Other Non Operating Income has averaged -$966.5 million across 5 years, with a median of -$739.0 million in 2025.
- Annual changes were most pronounced in 2023 — Other Non Operating Income surged 109.72% — and 2024, when it plunged 1576.0%.
- Pfizer's Other Non Operating Income stood at -$772.0 million in 2022, then jumped by 120.6% to $159.0 million in 2023, then tumbled by 1376.73% to -$2.0 billion in 2024, then tumbled by 122.36% to -$4.5 billion in 2025, then jumped by 80.93% to -$861.0 million in 2026.
- Business Quant data shows PFE's Other Non Operating Income at -$861.0 million in Q1 2026, -$4.5 billion in Q4 2025, and -$517.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -3.72 Bn |
| Mar 29, 2026 | -861.00 Mn |
| Dec 31, 2025 | -4.51 Bn |
| Sep 28, 2025 | -517.00 Mn |
| Jun 29, 2025 | -739.00 Mn |
| Mar 30, 2025 | -953.00 Mn |
| Sep 29, 2024 | -2.03 Bn |
| Jun 30, 2024 | -1.11 Bn |
| Mar 31, 2024 | -680.00 Mn |
| Dec 31, 2023 | 159.00 Mn |
| Jul 2, 2023 | 75.00 Mn |
| Apr 2, 2023 | -275.00 Mn |
| Jul 3, 2022 | -772.00 Mn |
| Apr 3, 2022 | -350.00 Mn |
| Oct 3, 2021 | 4.04 Bn |
| Jul 4, 2021 | 1.34 Bn |
| Apr 4, 2021 | 1.00 Bn |
| Sep 27, 2020 | -1.88 Bn |
| Jun 28, 2020 | 955.00 Mn |
| Mar 29, 2020 | 6.00 Mn |